Moffitt Cancer Center researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer.

Oncologists are increasingly favoring CAR T-cell therapy’s early-line use in relapsed/refractory multiple myeloma despite challenges like cost and access.

The Car-T cell therapy was tested on patients with B-cell leukaemia and lymphoma - rare types of blood cancers - that affect the bone marrow and the lymphatic system.

Moffitt Cancer Center researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer. The innovative approach targets human epidermal growth factor receptor ...

AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity. The ...

The clinical trial results of India’s first CAR T-cell therapy, published in The Lancet, show that it worked for nearly 73 ...

Researchers from Moffitt Cancer Center have found a new way to boost cancer immunotherapy by targeting a protein called ...

To enable this innovation, Medigene combined TCR-guided precision targeting with innate NK cell killing. The Company has developed a proprietary universal scaffold that allows its 3S TCRs to function ...

Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25; Deep and durable responses maintained over 12 months in ...

You will be redirected to our submission process. This Research Topic is part of the 15 Year Anniversary of Cellular Neuroscience series, organized in collaboration with the Neuroscience portfolio at ...

X-linked severe combined immunodeficiency disease (X-SCID) is a rare genetic disorder characterized by profound defects in ...

An international group of researchers has identified an important mechanism that enables stem cells to evade immune rejection ...